BlackRock Amends Nurix Therapeutics Stake as of Dec 31, 2023
Ticker: NRIX · Form: SC 13G/A · Filed: Jan 24, 2024 · CIK: 1549595
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock updated its Nurix Therapeutics stake, signaling a portfolio adjustment.**
AI Summary
BlackRock Inc. filed an amended Schedule 13G/A on January 24, 2024, indicating a change in its ownership of Nurix Therapeutics, Inc. common stock as of December 31, 2023. While the exact percentage change isn't detailed in the provided snippet, this amendment (Amendment No. 2) signals BlackRock's updated passive investment position. This matters to investors because BlackRock is a major institutional investor, and changes in its holdings can sometimes reflect its sentiment or portfolio rebalancing, potentially influencing other investors' perceptions of Nurix Therapeutics.
Why It Matters
This filing shows BlackRock's updated passive investment in Nurix Therapeutics, which can be a signal to the market about institutional interest in the company.
Risk Assessment
Risk Level: low — This is a routine amendment filing by a large institutional investor, indicating a passive investment change, not a hostile takeover or significant divestment.
Analyst Insight
Investors should note BlackRock's continued, albeit adjusted, passive stake in Nurix Therapeutics, but should seek the full filing to understand the exact change in ownership percentage before making investment decisions.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Nurix Therapeutics, Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 24, 2024 (date) — the filing date of the SC 13G/A
- 67080M103 (other) — the CUSIP number for Nurix Therapeutics, Inc. Common Stock
FAQ
What type of SEC filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' and 'SCHEDULE 13G (Amendment No: 2)' sections.
Who is the 'Subject Company' in this filing?
The 'Subject Company' is Nurix Therapeutics, Inc., as explicitly stated under the 'SUBJECT COMPANY: COMPANY DATA' section.
Who is the 'Filed By' entity in this document?
The 'Filed By' entity is BlackRock Inc., as indicated under the 'FILED BY: COMPANY DATA' section.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as specified in the filing.
What is the CUSIP Number for the securities mentioned?
The CUSIP Number for the Common Stock of Nurix Therapeutics, Inc. is 67080M103, as listed in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 24, 2024 regarding Nurix Therapeutics, Inc. (NRIX).